Friday, July 10, 2026

Drug profile · INN

bromocriptine mesylate

bromocriptine mesylate (BROMOCRIPTINE MESYLATE) is a d2-like dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — bromocriptine mesylate
US status
approved
Class
Route
ORAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

bromocriptine mesylate (BROMOCRIPTINE MESYLATE) is a d2-like dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN bromocriptine mesylate
Brand BROMOCRIPTINE MESYLATE
Mechanism D2-like dopamine receptor agonist
Target D2-like dopamine receptor
Route ORAL
Formulation CAPSULE

Mechanism of action

D2-like dopamine receptor agonist

Primary target: D2-like dopamine receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. bromocriptine Phase 2 · Ultragenyx UK · Stereotyped Behavior
  2. Bromocriptin 2.5mg, 2-3 times a day Unknown · Chinese Academy of · Pituitary Tumor

Related & competitor drugs

  1. chlorpromazine hydrochloride D2-like dopamine receptor antagonist
  2. droperidol D2-like dopamine receptor antagonist
  3. haloperidol Serotonin 2a (5-HT2a) receptor antagonist
  4. haloperidol decanoate D2-like dopamine receptor inverse agonist
  5. haloperidol lactate Serotonin 2a (5-HT2a) receptor antagonist
  6. loxapine hydrochloride D2-like dopamine receptor antagonist

Frequently asked questions

What is bromocriptine mesylate?

bromocriptine mesylate (BROMOCRIPTINE MESYLATE) is a d2-like dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for bromocriptine mesylate?

BROMOCRIPTINE MESYLATE is a marketed brand name for bromocriptine mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of bromocriptine mesylate?

bromocriptine mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.